{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T18:15:36Z","timestamp":1696270536480},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"vor","delay-in-days":397,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.jval.2012.06.005","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T13:31:02Z","timestamp":1344519062000},"page":"894-906","source":"Crossref","is-referenced-by-count":15,"title":["Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada"],"prefix":"10.1016","volume":"15","author":[{"given":"Jing","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Goeree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2012.06.005_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1155\/2011\/956763","article-title":"Hepatitis B awareness and education: a failing grade","volume":"25","author":"Burak","year":"2011","journal-title":"Can J Gastroenterol"},{"issue":"Suppl. C","key":"10.1016\/j.jval.2012.06.005_bib2","doi-asserted-by":"crossref","first-page":"5C","DOI":"10.1155\/2007\/910831","article-title":"Management of chronic hepatitis B: consensus guidelines","volume":"21","author":"Sherman","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib4","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1155\/2010\/931326","article-title":"Management of hepatitis B: a longitudinal national survey \u2013 impact of the Canadian Hepatitis B Consensus Guidelines","volume":"24","author":"Marotta","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2010.06.042","article-title":"Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses","volume":"139","author":"Woo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1524-4733.2010.00777.x","article-title":"Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B","volume":"13","author":"Dakin","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.06.005_bib7","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","year":"2006"},{"key":"10.1016\/j.jval.2012.06.005_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib10","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib11","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.06.005_bib12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"de Jongh","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1093\/oxfordjournals.aje.a009060","article-title":"Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers","volume":"145","author":"Yu","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jval.2012.06.005_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/gut.32.3.294","article-title":"Natural history and prognostic factors for chronic hepatitis type B","volume":"32","author":"Fattovich","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.jval.2012.06.005_bib15","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.06.005_bib16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib17","first-page":"803","article-title":"[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B]","volume":"14","author":"Wang","year":"2006","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.jval.2012.06.005_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4166\/kjg.2010.56.2.83","article-title":"[Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients]","volume":"56","author":"Cho","year":"2010","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib19","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s10620-010-1561-2","article-title":"Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudine-resistant chronic hepatitis B","volume":"56","author":"Chung","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"Suppl.","key":"10.1016\/j.jval.2012.06.005_bib20","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1097\/00004836-200411003-00011","article-title":"Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection","volume":"38","author":"Gagnon","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib21","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.06.005_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib24","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.06.005_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/jhep.2003.50117","article-title":"Durability of serologic response after lamivudine treatment of chronic hepatitis B","volume":"37","author":"Dienstag","year":"2003","journal-title":"Hepatology"},{"issue":"4, Suppl. 1","key":"10.1016\/j.jval.2012.06.005_bib27","first-page":"267A","article-title":"Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022)","volume":"42","author":"Gish","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1478-3231.2009.02198.x","article-title":"Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion","volume":"30","author":"Lau","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jval.2012.06.005_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1046\/j.1365-2893.2002.00357.x","article-title":"Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion","volume":"9","author":"Lee","year":"2002","journal-title":"J Viral Hepat"},{"issue":"Suppl.","key":"10.1016\/j.jval.2012.06.005_bib30","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0168-8278(08)60708-4","article-title":"Sustained durability of HBeAG seroconversion in chronic hepatitis B patients after treatment with telbivudine","volume":"48","author":"Poynard","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jval.2012.06.005_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2012.06.005_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jhep.2010.02.026","article-title":"Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease","volume":"53","author":"Eun","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jval.2012.06.005_bib35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2012.06.005_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s005350050331","article-title":"Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan","volume":"35","author":"Kato","year":"2000","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib38","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2011.01465.x","article-title":"Hepatitis B surface antigen monitoring and management of chronic hepatitis B","volume":"18","author":"Sonneveld","year":"2011","journal-title":"J Viral Hepat"},{"issue":"Suppl. 1","key":"10.1016\/j.jval.2012.06.005_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1055\/s-2005-915647","article-title":"Current treatment of chronic hepatitis B: benefits and limitations","volume":"25","author":"Perrillo","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jval.2012.06.005_bib41","first-page":"1","article-title":"Management of chronic hepatitis B","volume":"174","author":"Wilt","year":"2008","journal-title":"Evid Rep Technol Assess (Full Rep)"},{"key":"10.1016\/j.jval.2012.06.005_bib42","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12072-008-9048-3","article-title":"Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure","volume":"2","author":"Locarnini","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jval.2012.06.005_bib43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/hep.24078","article-title":"No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus","volume":"53","author":"Snow-Lampart","year":"2011","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jval.2012.06.005_bib44","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s10620-011-1610-5","article-title":"Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"56","author":"Ha","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jval.2012.06.005_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/carcin\/bgm252","article-title":"Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men","volume":"29","author":"Wu","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jval.2012.06.005_bib46","first-page":"4","article-title":"Viral hepatitis B and hepatocellular carcinoma","volume":"74","author":"Michielsen","year":"2011","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jval.2012.06.005_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4254\/wjh.v2.i3.91","article-title":"Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"2","author":"Tziomalos","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jval.2012.06.005_bib48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.1840130403","article-title":"Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study","volume":"13","author":"Liaw","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib49","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/0016-5085(94)90760-9","article-title":"A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal","volume":"106","author":"Villeneuve","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib50","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jval.2012.06.005_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.510310130","article-title":"Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B","volume":"31","author":"Villeneuve","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/jhep.2001.25271","article-title":"Liver transplantation in patients with hepatitis B virus infection: outcome in Asian versus white patients","volume":"34","author":"Teo","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jval.2012.06.005_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jval.2012.06.005_bib54","first-page":"418","article-title":"[Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea]","volume":"8","author":"Jung","year":"2002","journal-title":"Taehan Kan Hakhoe Chi"},{"key":"10.1016\/j.jval.2012.06.005_bib55","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1440-1746.2006.04707.x","article-title":"Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma","volume":"22","author":"Kuzuya","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jval.2012.06.005_bib56","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/lt.20217","article-title":"Outcome of liver transplantation for hepatitis B in the United States","volume":"10","author":"Kim","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jval.2012.06.005_bib57","first-page":"17","article-title":"Liver transplantation in the United States from 1987-1998: updated results from the Pitt-UNOS Liver Transplant Registry","author":"Seaberg","year":"1998","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jval.2012.06.005_bib60","series-title":"Ontario Drug Benefit Formulary\/Comparable Drug Index","year":"2008"},{"key":"10.1016\/j.jval.2012.06.005_bib61","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00019053-200826110-00006","article-title":"A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B","volume":"26","author":"Spackman","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2012.06.005_bib65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","article-title":"The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons","volume":"11","author":"Levy","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2012.06.005_bib66","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2012.06.005_bib67","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18553\/jmcp.2008.14.1.21","article-title":"Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients","volume":"14","author":"Yuan","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.jval.2012.06.005_bib68","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2009.04.013","article-title":"Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B","volume":"51","author":"Buti","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jval.2012.06.005_bib69","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10198-007-0078-x","article-title":"Decision-analytical modelling in health-care economic evaluations","volume":"9","author":"Sun","year":"2008","journal-title":"Eur J Health Econ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512016178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301512016178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T01:56:00Z","timestamp":1643162160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301512016178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1098301512016178"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2012.06.005","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}